CYCLOPHOSPHAMIDE IN RELAPSING REMITTING MULTIPLE-SCLEROSIS

被引：7

作者：

DANDREA, F

DAURIZIO, C

MARINI, C

PRENCIPE, M

机构：

[1] Clinica Neurologica dell'Università degli Studi, L'Aquila

来源：

ITALIAN JOURNAL OF NEUROLOGICAL SCIENCES | 1990年 / 11卷 / 03期

关键词：

immunosuppressive therapy; Multiple sclerosis;

D O I：

10.1007/BF02333857

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

7 patients with relapsing-remitting multiple sclerosis (MS) were subjected to an intensive course of intravenous (I.V.) cyclophosphamide (CY) therapy. All patients received induction therapy with 11 daily doses of 300 mg/m2 and then a single dose every six months for three years. After one year of follow-up all patients showed a decrease in relapse rate (0.57.57); in the two subsequent years of follow-up 2 patients showed a mild worsening while the others were clinically stable. As suggested by others, our results indicate that I.V. CY therapy may influence the clinical course of relapsing-remitting MS. © 1990 Masson Italia Periodici.

引用

页码：271 / 274

页数：4

共 19 条

[1]

Austin H.A., Klippel J.H., Balow J.E., Et al., Therapy of lupus nephritis: controlled trial of prednisone and citotoxic drugs, N. Engl J Med, 314, pp. 614-619, (1986)

[2]

Carter J.L., Dawson D.M., Hafler D.A., Et al., Five-years experience with intensive immunosuppression in progressive multiple sclerosis using high dose IV cyclophosphsmide plus ACTH, Neurology, 36, (1986)

[3]

Confavreux C., Aimard G., Devic M., Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients, Brain, 103, pp. 281-300, (1980)

[4]

Godkin D.E., Plencner S., Palmer-Sawerud J., Et al., Cyclophosphamide in chronic progressive multiple sclerosis, maintenance vs non-maintenance therapy, Arch Neurol, 44, pp. 1096-1104, (1987)

[5]

Gonsette R.E., Demonty L., Delmotte P., Intensive immunosuppression with cyclophosphamide in multiple sclerosis: a follow-up of 110 patients for two to six years, J. Neurol, 214, pp. 173-181, (1977)

[6]

Hauser S., Dawon D., Weiner H.L., Et al., Intensive immunosuppression in progressive multiple sclerosis: A randomized three arm study of high dose intravenous cyclophosphamide, plasma exchange and ACTH, N. Engl. J. Med., 308, pp. 173-180, (1983)

[7]

Hommes O.R., Lamers K.J.B., Reekers P., Effect of intensive immunosuppression on the course of chronic progressive multiple sclerosis, J. Neurol., 223, pp. 177-190, (1980)

[8]

Khatri B.O., McQuillel M.D., Harrington G.J., Et al., Chronic progressive multiple sclerosis: Double blinded controlled study of plasmapheresis in patients taking immunosuppressive drugs, Neurology, 35, pp. 312-319, (1985)

[9]

Killian J.M., Bresler R.B., Artrong R.M., A controlled pilot trial of monthly intravenous cyclophosphamide in multiple sclerosis, Arch. Neurol., 45, pp. 27-30, (1988)

[10]

Kurzke J.F., Rating neurological impairment in MS: an expanded disability status scale, Neurology, 33, pp. 1444-1452, (1983)

← 1 2 →